An observational study in Chronic Subdural Hematoma and Hemorrhage Brain, sponsored by Ohio State University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Ohio State University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Hematoma, Subdural, Chronic with a site in United States — 10 open to participants now, 10 under way, none of them phase 3. Hematoma, Subdural, Chronic · United States.
Among the 22 studies in Hematoma, Subdural, Chronic with a site in United States, this one is one of 4 that started in 2025, is one of 7 observational ones, and was the 18th registered.
113 studies on the registry are indexed under Hematoma, Subdural, Chronic; 50 are open to participants now.
Browse Hematoma, Subdural, Chronic studies →10 of the 22 studies in Hematoma, Subdural, Chronic with a site in United States are open now. Recruiting first, the newest first:
Arsenal Medical, Inc. · Sites in United States
Ages 18–90
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Lahey Clinic · Sites in United States
Ages 18+
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 40–90
Carilion Clinic · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Hematoma, Subdural, Chronic studies recruiting now, 26 (72%) set no upper age limit and 1 (3%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 1
First in 2014; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 210 across 20 observational studies indexed under Hematoma, Subdural, Chronic.
Median enrollment 40 across the 15 interventional studies, 100 across the 7 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
Ohio State University is the lead sponsor of 664 studies on the registry; 149 are open to participants now.
Of its 67 completed or terminated interventional studies of FDA-regulated products, 49 (73%) have results posted.
Ohio State University has 1 study filed under Hematoma, Subdural, Chronic — fewer than ten, so there is no comparison to draw.
3 of the studies in Hematoma, Subdural, Chronic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07214623Kaneka Medical America LLCProspective Multi-center Single Arm Study for Subjects With Chronic Subdural Hematoma Treated With i-ED COILs, Either Alone or in Combination With Burr-holes or Mini-craniotomy | 2026-11-30 |
| NCT06181994Montefiore Medical CenterMiddle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH) | 2026-12 |
| NCT07715656Lahey ClinicAssessing Outcomes of Coil Embolization for Unilateral vs Bilateral Chronic Subdural Hematomas | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies in Hematoma, Subdural, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the function of matched pair Aristotle 14 Guidewire and Plato Microcatheter in MMA embolization treatment for chronic subdural hematoma compared to surgeon's preference
If you agree to take part, you will have a 50/50 chance of being assigned to one of two groups. In group 1, your procedure will use the study devices. In group 2, your procedure will use devices chosen by your surgeon. The procedure and follow up are part of standard medical care. This means that taking part in the study will not mean more time or energy compared to the usual treatment you would have.
Patients admitted to The Ohio State University Wexner Medical Center
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized in 1:1 ratio to either use of study devices (matched pair Aristotle and Plato) or standard of care (surgeon combination preference) using block randomization method with a fixed block size of 4 ensuring 50% will be randomized to study devices group and 50% randomized to standard of care group.
Surgeon will decide the on guidewire and microcatheter to use for MMA embolization
Total Navigation/procedure time
Comparing between devices on both navigation and procedure time
Time frame: 2 years
Final Embolization Grades
Comparison between device groups for final embolization grades
Time frame: 2 Years
Incidence of AE at time of surgery
Incidence of device related adverse events and incidence of procedure related adverse events
Time frame: 2 Years
Incidence of recurrence of hemorrhage
Incidence of hematoma reoccurrence/progression requiring re-intervention at 90 day follow-up
Time frame: 2 Years
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Jul 2028, 31 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.